Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the renewal of agreements for continuing connected transactions and related party transactions. These agreements, set to run from January 2025 to December 2027, involve key parties like Shandong Lukang and Perrigo Company, ensuring the ongoing procurement and supply of pharmaceutical products. Investors should note that these transactions have been approved by the board and are conducted on normal commercial terms.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
